Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

68Ga-PSMA-617 Compared With 68Ga-RM2 and 18F-FCholine PET/CT for the Initial Staging of High-Risk Prostate Cancer

Schollhammer, Romain MD*; de Clermont Gallerande, Henri MD*; Robert, Grégoire MD, PhD; Yacoub, Mokrane MD; Vimont, Delphine MSc*; Hindié, Elif MD, PhD*; Fernandez, Philippe MD, PhD*; Morgat, Clément PharmD, PhD*

doi: 10.1097/RLU.0000000000002672
Interesting Images

68Ga-labeled prostate-specific membrane antigen inhibitors and 68Ga-labeled gastrin-releasing peptide receptor antagonists showed interesting results for staging biochemically recurrent prostate cancer. In this case, 68Ga–prostate-specific membrane antigen-617 PET/CT, 68Ga-RM2 PET/CT, and 18F-choline PET/CT were performed in a patient (66-year-old man, prostate-specific antigen = 6.7 ng/mL) with biopsy-proven Gleason 9 (5 + 4) prostate cancer, candidate for radical prostatectomy and lymph node dissection.

From the *Nuclear Medicine Department, University Hospital of Bordeaux and INCIA, University of Bordeaux

Departments of Urology

Pathology, University Hospital of Bordeaux, Bordeaux, France.

Received for publication January 3, 2019; revision accepted May 3, 2019.

Conflict of interest and sources of funding: This study was funded by the University Hospital of Bordeaux under grant AOI 2016 and was achieved within the context of the Laboratory of Excellence TRAIL ANR-10-LABX-57. None declared to all authors.

Correspondence to: Clément Morgat, PharmD, PhD, Nuclear Medicine Department, University Hospital of Bordeaux, Place Amélie Raba Léon, 33076 Bordeaux, France. E-mail:

Online date: June 26, 2019

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.